The reversal of RBC-exacerbated atherosclerosis by the ferroptosis inhibitor Liprox-1 suggests a potential treatment to reduce CVD risk in JAK2-mutant myeloproliferative disorders, in patients with JAK2VF clonal hematopoiesis, and even more broadly in patients with elevated hematocrit and coronary artery disease. The gene discussed is JAK2; the disease is myeloproliferative disorder.